Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2000
10/18/2000EP1044022A2 Compositions and methods for targeted delivery of factors
10/18/2000EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/18/2000EP1044015A1 Formulations for amylin agonist peptides
10/18/2000EP1044014A1 Agent for treating allergic or hypersensitivity condition
10/18/2000EP1044008A1 Use of aliphatic polyamines for reducing oxalate
10/18/2000EP1044006A1 Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection
10/18/2000EP1044004A1 A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
10/18/2000EP1044001A1 Integrin receptor antagonists
10/18/2000EP1044000A1 Combination therapy for the treatment of aids
10/18/2000EP1043993A2 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
10/18/2000EP1043991A1 Treatment for alzheimer's disease
10/18/2000EP1043989A1 Use of mek1 inhibitors as protective agents against damage due to ischemia
10/18/2000EP1043980A2 Method of reducing craving in mammals
10/18/2000EP1043977A1 Oral pharmaceutical pulsed release dosage form
10/18/2000EP0979090A4 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine
10/18/2000EP0726704B1 Method of introducing material into eggs during early embryonic development
10/18/2000EP0467932B1 Urokinase-type plasminogen activator receptor
10/18/2000CN1270632A APPIL-a novel protein with growth effects
10/18/2000CN1270528A Nootropic agent
10/18/2000CN1270527A Use of neurotoxin therapy for treatment of urologic and related disorders
10/18/2000CN1270526A Metal compounds, mixed or sulphated as phosphate binders
10/18/2000CN1270520A Treatment of oppositional defiant disorder
10/18/2000CN1270029A Thebaic analgesic with controllable releasement of active content
10/18/2000CN1270028A Analgesic with controlled releasement of active content
10/17/2000US6133437 Antisense nucleic acid which is complementary to specific human and mouse nucleotide sequences and suppresses the biological activity of inhibitor of apoptosis in vitro; anticarcinogenic agents
10/17/2000US6133326 Compositions and methods for decreasing sebum production
10/17/2000US6133324 Use of perillyl alcohol in organ transplantation
10/17/2000US6133320 Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
10/17/2000US6133316 Nitric oxide synthetase inhibitor or nitric oxide antagonist to reduce or eliminate unwanted physiological effects encountered with the parenteral administration of particulate drugs such as contrast agents for ultrasonic imaging
10/17/2000US6133309 Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists
10/17/2000US6133304 Treating fibrosis, ventricular dilation, and/or heart failure in a mammal by administering an antifibrotic amount of a mixture of an angiotensin-converting enzyme(ace) inhibitor and at least one matrix metalloproteinase(mmp) inhibitor
10/17/2000US6133295 Pharmaceutical composition
10/17/2000US6133293 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action; potent depressive effect on diabetic hyperglycemia; 2,4-thiazolidinediones and oxazolidinediones
10/17/2000US6133291 3-(piperidin-1-ylalkylene)imidazole derivatives; glaucoma, antiallergens; antiinflammation and hypotensive agents, sleeping disorders; hypermotility of the gastrointestinal tract, alzheimer's disease, schizophrenia and
10/17/2000US6133272 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
10/17/2000US6133247 Method of detecting lung disease
10/17/2000US6132987 Polypeptide associated with macrophages; for diagnosis and treatment of inflammation, arthritis and atherosclerosis
10/17/2000US6132980 Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes
10/17/2000US6132789 For vaccine formulations as adjuvants and/or delivery systems, to enhance immune response to immunogens in animal such as human
10/17/2000US6132771 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
10/17/2000US6132768 Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
10/17/2000US6132730 Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
10/17/2000US6132729 Coagulation-deficient tissue factor for use in effecting specific coagulation and for use in tumor treatment
10/17/2000US6132724 Allelic polygene diagnosis of reward deficiency syndrome and treatment
10/17/2000US6132722 Recombinant antibody-enzyme fusion proteins
10/12/2000WO2000060117A2 Prediction of risk of interstitial lung disease
10/12/2000WO2000060109A1 Amplification of cyp24 and uses thereof
10/12/2000WO2000060100A1 Dsp-9 dual-specificity map kinase phosphatase
10/12/2000WO2000060099A1 Dsp-4 dual-specificity map kinase phosphatase
10/12/2000WO2000060098A1 Dsp-7 dual-specificity map kinase phosphatase
10/12/2000WO2000060082A2 Vesicle associated proteins
10/12/2000WO2000060080A2 Molecules of the immune system
10/12/2000WO2000060077A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
10/12/2000WO2000059942A2 Human obesity protein binding protrein-2 homolog and uses thereof
10/12/2000WO2000059936A1 Human neurogenin 3-encoding nucleotide sequences
10/12/2000WO2000059930A1 A method of treating cancer
10/12/2000WO2000059929A1 Macrocyclic peptides active against the hepatitis c virus
10/12/2000WO2000059547A2 Method of detecting endometriosis
10/12/2000WO2000059542A1 Method for a programmed controlled ovarian stimulation protocol
10/12/2000WO2000059541A1 Preventives or remedies for cancer and method for screening the same
10/12/2000WO2000059539A1 Method and means for treating post-polio syndrome
10/12/2000WO2000059536A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/12/2000WO2000059525A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
10/12/2000WO2000059517A1 Ceramide and chemotherapeutic agents for inducing cell death
10/12/2000WO2000059515A2 Immunomodulating polymers
10/12/2000WO2000059506A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD
10/12/2000WO2000059504A1 Method for the treatment of neurological or neuropsychiatric disorders
10/12/2000WO2000059493A2 Improved dialysis solutions and methods
10/12/2000WO2000059491A2 Methods for modulating the human sexual response
10/12/2000WO2000059490A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions
10/12/2000WO2000059489A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
10/12/2000WO2000059486A2 Use of cyp2d6 inhibitors in combination therapies
10/12/2000WO2000059485A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
10/12/2000WO2000059481A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
10/12/2000WO2000059479A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/12/2000WO2000059462A1 Composition for cosmetic and dermatological skin care
10/12/2000WO2000059448A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000WO2000059447A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
10/12/2000WO2000059424A1 Vacuum assisted closure system with provision for introduction of agent
10/12/2000WO2000059304A1 Compositions and methods for preventing and treating sexual dysfunctions
10/12/2000WO2000038747A3 Absorbent article composition and method of use for sequestering skin irritants
10/12/2000WO2000037037A3 Composition for treatment of burns
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO2000027196B1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
10/12/2000WO2000020587A3 Cancer associated antigens and uses therefor
10/12/2000WO2000020446A3 Bax-mediated apoptosis modulating reagents and methods
10/12/2000WO2000017232A3 Regulatory protein from human keratinocytes
10/12/2000WO2000015790A9 Leptin induced genes
10/12/2000WO2000002549A3 Composition for and method of treating neurological disorders
10/12/2000WO1998025597A3 Method for treating and preventing heart failure and ventricular dilatation
10/12/2000DE19916176A1 Neue essentielle bakterielle Gene und ihre Proteine New essential bacterial genes and their proteins
10/12/2000DE10004815A1 Human sodium-phosphate cotransporter Npt2B, useful e.g. for identifying agents for treating hyper- and hypo-phosphatemia, and related nucleic acid
10/12/2000CA2369024A1 Negative pressure wound therapy system with provision for introduction of agent
10/12/2000CA2368367A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/12/2000CA2368017A1 Use of erbb receptor ligands in treating diabetes
10/12/2000CA2367403A1 Dsp-9 dual-specificity map kinase phosphatase
10/12/2000CA2367378A1 Molecules of the immune system
10/12/2000CA2367294A1 Prediction of risk of interstitial lung disease
10/12/2000CA2367109A1 Dsp-4 dual-specificity map kinase phosphatase
10/12/2000CA2367104A1 Dsp-7 dual-specificity map kinase phosphatase
1 ... 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 ... 1151